Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial

被引:67
作者
Diepeveen, SHA
Verhoeven, GWHE
Van der Palen, J
Dikkeschei, LD
Van Tits, LJ
Kolsters, G
Offerman, JJG
Bilo, HJG
Stalenhoef, AFH
机构
[1] Isala Clin, Dept Internal Med, Zwolle, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Dept Nephrol, Nijmegen, Netherlands
[3] Med Spectrum Twente, Dept Epidemiol, Enschede, Netherlands
[4] Isala Clin, Dept Clin Chem, Zwolle, Netherlands
[5] Radboud Univ Nijmegen Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands
关键词
dialysis; lipoproteins; oxidative stress; randomised-controlled trial; statin; vitamin E;
D O I
10.1111/j.1365-2796.2005.01484.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. The objective of this study was to examine the effects of treatment with atorvastatin, alpha-tocopherol and the combination of both, on lipoproteins and oxidative stress in dialysis patients. Design and setting. This double-blind randomised placebo-controlled trial was performed at the dialysis department of a non-university hospital. Subjects, intervention and measurements. A total of 44 clinically stable, non-diabetic patients on dialysis therapy (23 on haemo- and 21 on peritoneal-dialysis) without manifest cardiovascular disease were included in this study. They were randomised for treatment during a period of 12 weeks with 40 mg atorvastatin + placebo alpha-tocopherol (group 1) once daily, 800 IU alpha-tocopherol + placebo atorvastatin once daily (group 2), 40 mg atorvastatin + 800 IU alpha-tocopherol once daily (group 3), or placebo atorvastatin + placebo alpha-tocopherol once daily (group 4). Assessment of lipid profile and oxidative stress was performed at the start of the study and after 12 weeks of treatment. Results. Treatment with atorvastatin reduced total cholesterol, triglycerides (TG), low-density lipoprotein (LDL) cholesterol, apolipoprotein B (apoB) and levels of oxidised LDL (oxLDL) with 30-43%. It had no influence on LDL oxidisability. Additional supplementation with alpha-tocopherol had no effect on lipid profile and oxLDL levels but decreased in vitro LDL oxidisability. No side-effects were observed. Conclusions. Treatment with atorvastatin is effective in lowering plasma total cholesterol, TG, LDL, apoB and oxLDL in a population of stable dialysis patients and might therefore be an effective tool in improving the poor cardiovascular outcome in these patients. Supplementation of alpha-tocopherol to atorvastatin had beneficial effects on in vitro LDL oxidisability and might therefore be of additional value. Further research on the clinical effects of treatment with atorvastatin in combination with alpha-tocopherol is necessary.
引用
收藏
页码:438 / 445
页数:8
相关论文
共 24 条
  • [1] Dialysis modalities and dyslipidemia
    Attman, PO
    Samuelsson, O
    Johansson, AC
    Moberly, JB
    Alaupovic, P
    [J]. KIDNEY INTERNATIONAL, 2003, 63 : S110 - S112
  • [2] Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
    Boaz, M
    Smetana, S
    Weinstein, T
    Matas, Z
    Gafter, U
    Iaina, A
    Knecht, A
    Weissgarten, Y
    Brunner, D
    Fainaru, M
    Green, MS
    [J]. LANCET, 2000, 356 (9237) : 1213 - 1218
  • [3] Cardiovascular disease in end-stage renal disease patients
    Collins, AJ
    Li, SL
    Ma, JZ
    Herzog, C
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S26 - S29
  • [4] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
  • [5] Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5
  • [6] Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small dense low-density lipoprotein formation
    Deighan, CJ
    Caslake, MJ
    McConnell, M
    Boulton-Jones, JM
    Packard, CJ
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (05) : 852 - 862
  • [7] The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification - Studies on subjects with familial combined hyperlipidemia
    deRijke, YB
    Bredie, SJH
    Demacker, PNM
    Vogelaar, JM
    HakLemmers, HLM
    Stalenhoef, AFH
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (01) : 127 - 133
  • [8] A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD
    Harris, KPG
    Wheeler, DC
    Chong, CC
    [J]. KIDNEY INTERNATIONAL, 2002, 61 (04) : 1469 - 1474
  • [9] The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
    Himmelfarb, J
    Stenvinkel, P
    Ikizler, TA
    Hakim, RM
    [J]. KIDNEY INTERNATIONAL, 2002, 62 (05) : 1524 - 1538
  • [10] Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis
    Hocher, B
    Ziebig, R
    Altermann, C
    Krause, R
    Asmus, G
    Richter, CM
    Slowinski, T
    Sinha, P
    Neumayer, HH
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (09): : 2329 - 2337